Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation
Cancer Medicine · 2025-05 · 14 (9)
DOI: 10.1002/cam4.70914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 02.05.2025. Verfasst von Kunmin Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Clinical Research Center of Traditional Chinese Medicine Oncology, Science and Technology Commission of Shanghai Municipality, High-Level Traditional Chinese Medicine Key Discipline Construction Project of the National Administration of Traditional Chinese Medicine, Youth Talent Project of Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Background
The relationship between hepatocellular carcinoma (HCC) and gut microbiota has gained attention for its impact on HCC immunotherapy.
Methods
Key gut microbial metabolites, including bile acids, toll‐like receptor 4, short‐chain fatty acids, and bacterial toxins, contribute to HCC progression and influence immune responses through the gut‐liver axis. As immune checkpoint inhibitors (ICIs) become common in HCC treatment, modulating the gut microbiota offers new strategies to enhance ICIs efficacy. However, individual differences in microbial composition introduce challenges, with some HCC patients showing resistance to ICIs.
Results
This review summarizes the latest findings on the role of gut microbiota in HCC and explores emerging therapeutic approaches, including fecal microbiota transplantation, probiotics, antibiotics, and natural compounds.
Conclusions
The focus is on translating these insights into personalized medicine to optimize ICIs responses and improve HCC treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.
- Department of Emergency, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Kunmin Xiao
Förderung
- Shanghai Clinical Research Center of Traditional Chinese Medicine Oncology, Science and Technology Commission of Shanghai Municipality
- High-Level Traditional Chinese Medicine Key Discipline Construction Project of the National Administration of Traditional Chinese Medicine
- Youth Talent Project of Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine
Zitieren
APA
Xiao, K., Li, K., Xiao, K., Yang, J., & Zhou, L. (2025). Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation. Cancer Medicine, 14(9). https://doi.org/10.1002/cam4.70914
Vancouver
Xiao K, Li K, Xiao K, Yang J, Zhou L. Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation. Cancer Medicine. 2025;14(9). doi:10.1002/cam4.70914
BibTeX
@article{Xiao2025,
author = {Xiao, Kunmin and Li, Kexin and Xiao, Kunlin and Yang, Jinzu and Zhou, Lei},
title = {Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {9},
doi = {10.1002/cam4.70914}
}
EUVIMED